Lebrikizumab
17789
Phase 3 mab completed
Quick answer
Lebrikizumab for Atopic Dermatitis is a Phase 3 program (mab) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly and Company
- Indication
- Atopic Dermatitis
- Phase
- Phase 3
- Modality
- mab
- Status
- completed